138 related articles for article (PubMed ID: 34905632)
1. Prostate weight and prostate cancer outcomes after radical prostatectomy: Results from the SEARCH cohort study.
Barlow SK; Oyekunle T; Janes JL; De Hoedt AM; Aronson WJ; Kane CJ; Amling CL; Cooperberg MR; Klaassen ZW; Terris MK; Freedland SJ; Csizmadi I
Prostate; 2022 Feb; 82(3):366-372. PubMed ID: 34905632
[TBL] [Abstract][Full Text] [Related]
2. Obesity, race, and long-term prostate cancer outcomes.
Vidal AC; Oyekunle T; Howard LE; De Hoedt AM; Kane CJ; Terris MK; Cooperberg MR; Amling CL; Klaassen Z; Freedland SJ; Aronson WJ
Cancer; 2020 Aug; 126(16):3733-3741. PubMed ID: 32497282
[TBL] [Abstract][Full Text] [Related]
3. Positive surgical margins in radical prostatectomy patients do not predict long-term oncological outcomes: results from the Shared Equal Access Regional Cancer Hospital (SEARCH) cohort.
Mithal P; Howard LE; Aronson WJ; Terris MK; Cooperberg MR; Kane CJ; Amling C; Freedland SJ
BJU Int; 2016 Feb; 117(2):244-8. PubMed ID: 26010160
[TBL] [Abstract][Full Text] [Related]
4. Diabetes and Prostate Cancer Outcomes in Obese and Nonobese Men After Radical Prostatectomy.
Kelkar S; Oyekunle T; Eisenberg A; Howard L; Aronson WJ; Kane CJ; Amling CL; Cooperberg MR; Klaassen Z; Terris MK; Freedland SJ; Csizmadi I
JNCI Cancer Spectr; 2021 Jun; 5(3):. PubMed ID: 34169227
[TBL] [Abstract][Full Text] [Related]
5. Nomogram Predicting Prostate Cancer-specific Mortality for Men with Biochemical Recurrence After Radical Prostatectomy.
Brockman JA; Alanee S; Vickers AJ; Scardino PT; Wood DP; Kibel AS; Lin DW; Bianco FJ; Rabah DM; Klein EA; Ciezki JP; Gao T; Kattan MW; Stephenson AJ
Eur Urol; 2015 Jun; 67(6):1160-1167. PubMed ID: 25301759
[TBL] [Abstract][Full Text] [Related]
6. Poorly controlled diabetes increases the risk of metastases and castration-resistant prostate cancer in men undergoing radical prostatectomy: Results from the SEARCH database.
Nik-Ahd F; Howard LE; Eisenberg AT; Aronson WJ; Terris MK; Cooperberg MR; Amling CL; Kane CJ; Freedland SJ
Cancer; 2019 Aug; 125(16):2861-2867. PubMed ID: 31034601
[TBL] [Abstract][Full Text] [Related]
7. Can post-treatment free PSA ratio be used to predict adverse outcomes in recurrent prostate cancer?
Goldberg H; Glicksman R; Woon D; Hoffman A; Shaikh H; Chandrasekar T; Klaassen Z; Wallis CJD; Ahmad AE; Sanmamed-Salgado N; Qu X; Moraes FY; Diamandis EP; Berlin A; Fleshner NE
BJU Int; 2021 Jun; 127(6):654-664. PubMed ID: 32926761
[TBL] [Abstract][Full Text] [Related]
8. Are biochemical recurrence outcomes similar after radical prostatectomy and radiation therapy? Analysis of prostate cancer-specific mortality by nomogram-predicted risks of biochemical recurrence.
Lee BH; Kibel AS; Ciezki JP; Klein EA; Reddy CA; Yu C; Kattan MW; Stephenson AJ
Eur Urol; 2015 Feb; 67(2):204-9. PubMed ID: 25294696
[TBL] [Abstract][Full Text] [Related]
9. Cigarette smoking is associated with an increased risk of biochemical disease recurrence, metastasis, castration-resistant prostate cancer, and mortality after radical prostatectomy: results from the SEARCH database.
Moreira DM; Aronson WJ; Terris MK; Kane CJ; Amling CL; Cooperberg MR; Boffetta P; Freedland SJ
Cancer; 2014 Jan; 120(2):197-204. PubMed ID: 24127391
[TBL] [Abstract][Full Text] [Related]
10. EAU guidelines on prostate cancer. Part II: Treatment of advanced, relapsing, and castration-resistant prostate cancer.
Heidenreich A; Bastian PJ; Bellmunt J; Bolla M; Joniau S; van der Kwast T; Mason M; Matveev V; Wiegel T; Zattoni F; Mottet N;
Eur Urol; 2014 Feb; 65(2):467-79. PubMed ID: 24321502
[TBL] [Abstract][Full Text] [Related]
11. Impact of surgical margin status on prostate-cancer-specific mortality.
Chalfin HJ; Dinizo M; Trock BJ; Feng Z; Partin AW; Walsh PC; Humphreys E; Han M
BJU Int; 2012 Dec; 110(11):1684-9. PubMed ID: 22788795
[TBL] [Abstract][Full Text] [Related]
12. First-year weight loss with androgen-deprivation therapy increases risks of prostate cancer progression and prostate cancer-specific mortality: results from SEARCH.
Griffin K; Csizmadi I; Howard LE; Pomann GM; Aronson WJ; Kane CJ; Amling CL; Cooperberg MR; Terris MK; Beebe-Dimmer J; Freedland SJ
Cancer Causes Control; 2019 Mar; 30(3):259-269. PubMed ID: 30701374
[TBL] [Abstract][Full Text] [Related]
13. Does Early Prostate Specific Antigen Doubling Time after Radical Prostatectomy, Calculated Prior to Prostate Specific Antigen Recurrence, Correlate with Prostate Cancer Outcomes? A Report from the SEARCH Database Group.
Teeter AE; Griffin K; Howard LE; Aronson WJ; Terris MK; Kane CJ; Amling CL; Cooperberg MR; Freedland SJ
J Urol; 2018 Mar; 199(3):713-718. PubMed ID: 28870860
[TBL] [Abstract][Full Text] [Related]
14. Long-term cancer control outcomes in patients with biochemical recurrence and the impact of time from radical prostatectomy to biochemical recurrence.
Pompe RS; Gild P; Karakiewicz PI; Bock LP; Schlomm T; Steuber T; Graefen M; Huland H; Tian Z; Tilki D
Prostate; 2018 Jun; 78(9):676-681. PubMed ID: 29570821
[TBL] [Abstract][Full Text] [Related]
15. Obesity and prostate cancer-specific mortality after radical prostatectomy: results from the Shared Equal Access Regional Cancer Hospital (SEARCH) database.
Vidal AC; Howard LE; Sun SX; Cooperberg MR; Kane CJ; Aronson WJ; Terris MK; Amling CL; Freedland SJ
Prostate Cancer Prostatic Dis; 2017 Mar; 20(1):72-78. PubMed ID: 27698439
[TBL] [Abstract][Full Text] [Related]
16. Thresholds for PSA doubling time in men with non-metastatic castration-resistant prostate cancer.
Howard LE; Moreira DM; De Hoedt A; Aronson WJ; Kane CJ; Amling CL; Cooperberg MR; Terris MK; Freedland SJ
BJU Int; 2017 Nov; 120(5B):E80-E86. PubMed ID: 28371163
[TBL] [Abstract][Full Text] [Related]
17. Laparoscopic and robotic-assisted versus open radical prostatectomy for the treatment of localised prostate cancer.
Ilic D; Evans SM; Allan CA; Jung JH; Murphy D; Frydenberg M
Cochrane Database Syst Rev; 2017 Sep; 9(9):CD009625. PubMed ID: 28895658
[TBL] [Abstract][Full Text] [Related]
18. Monocyte counts and prostate cancer outcomes in white and black men: results from the SEARCH database.
Yirga A; Oyekunle T; Howard LE; De Hoedt AM; Cooperberg MR; Kane CJ; Aronson WJ; Terris MK; Amling CL; Taioli E; Fowke JH; Klaanssen Z; Freedland SJ; Vidal AC
Cancer Causes Control; 2021 Feb; 32(2):189-197. PubMed ID: 33392907
[TBL] [Abstract][Full Text] [Related]
19. New Prostate Cancer Grading System Predicts Long-term Survival Following Surgery for Gleason Score 8-10 Prostate Cancer.
Ham WS; Chalfin HJ; Feng Z; Trock BJ; Epstein JI; Cheung C; Humphreys E; Partin AW; Han M
Eur Urol; 2017 Jun; 71(6):907-912. PubMed ID: 27876305
[TBL] [Abstract][Full Text] [Related]
20. Detectable prostate-specific antigen Nadir during androgen-deprivation therapy predicts adverse prostate cancer-specific outcomes: results from the SEARCH database.
Keto CJ; Aronson WJ; Terris MK; Presti JC; Kane CJ; Amling CL; Freedland SJ
Eur Urol; 2014 Mar; 65(3):620-7. PubMed ID: 23245686
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]